AstraZeneca has won a legal battle in the US temporarily preventing the launch of a generic version of Pulmicort Respules, its childhood asthma drug with annual sales of about $1bn (£675m).

The US District Court of New Jersey granted the Anglo-Swedish pharmaceuticals group a temporary restraining order against a venture by Canadian group Apotex to launch a generic version of the medicine until further notice.